Randomized controlled trials of aspirin conducted among patients with cardiovascular disease found statistically significant reductions in circulating concentrations of high-sensitivity C-reactive protein (CRP), tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), and thromboxane B2 (TXB2) [61–63]. Here, TNF is linked to cardiovascular disorder.